LFG
AMLX icon

Larson Financial Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Larson Financial Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.55K Sell
142
-59
-29% -$912 ﹤0.01% 3043
2026
Q1 		$2.79K Buy
201
+160
+390% +$2.25K ﹤0.01% 2860
2025
Q4 		$495 Buy
+41
New +$557 ﹤0.01% 3126

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Larson Financial Group's AMLX Position: Q2 2026 in Review

Larson Financial Group reduced its Amylyx Pharmaceuticals (AMLX) stake by 29% in Q2 2026, selling an estimated $912 and leaving 142 shares worth $2.55K. The position accounts for ﹤0.01% of the portfolio, ranked #3043.

Larson Financial Group first reported a position in AMLX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.79K in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Larson Financial Group held 142 shares of Amylyx Pharmaceuticals worth $2.55K as of Q2 2026.
  • Larson Financial Group sold 59 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $912.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3043 holding.
  • Larson Financial Group first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Larson Financial Group's Amylyx Pharmaceuticals position peaked at $2.79K in Q1 2026.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.